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Keywords: stat; cytokine; dierentiation; survival; tyrosine kinase Mutant cytokine receptors lacking Stat recruitment sites fail to induce dierentiation gp130-based receptor system IL-6 and the related cytokines LIF, CNTF, OSM, IL-11 and CT-1 share structural features and aect an overlapping set of target cells . The receptors for the IL-6 family of cytokines share a signal transducing subunit known as gp130, which provides a link to multiple signaling pathways via a tyrosine phosphorylation-dependent mechanism. This familiar signaling paradigm, shared by all of the cytokine receptor systems discussed here, is initiated by liganddependent receptor oligomerization, activation of receptor-associated tyrosine kinases, and phosphorylation of speci®c tyrosine residues within the receptor. A subset of these receptor phosphotyrosines recruit cytoplasmic Stats through their SH2 domains. The Stats are then phosphorylated by receptor-associated kinases, inducing dimerization, nuclear translocation, and transcriptional activation at speci®c promoter elements. As described in more detail below, regions of gp130 required for myeloid dierentiation are often required for Stat activation.
The cytoplasmic region of gp130 responsible for Stat3 activation is also required for dierentiation signaling in the murine leukemia cell line, M1 . Both IL-6 and LIF induce growth arrest and macrophage dierentiation in this cell line. To avoid the complication of signaling from endogenous gp130, chimeric receptors were constructed in which the cytoplasmic region of gp130 was fused to the extracellular ligand-binding domain of growth hormone. The resulting chimeric receptor generated growth hormone-dependent signals for growth arrest and morphological changes indistinguishable from those of IL-6. Successive C-terminal truncations of the chimeric receptor identi®ed the distal 133 residues of gp130 as critical for the generation of signals for growth arrest, macrophage dierentiation, and Stat3 activation. Phosphorylation of Tyr 126 in this region of gp130 forms a binding site for the Stat3 SH2 domain (Y P XXQ motif) (Stahl et al., 1995) . Mutagenesis of this site completely blocked dierentiation signaling and Stat3 activation from the truncated receptor. However, mutagenesis of Tyr 126 did not interfere with Stat3 activation and dierentiation signaling from the fulllength receptor chimera, indicating that tyrosine residues comprising other Y P XXQ motifs in the distal portion of gp130 could complement the loss of the Stat3 binding site at Tyr 126. Mutation of all six tyrosine residues within the cytoplasmic region of the full-length gp130 chimera abolished Stat activation and dierentiation signaling, consistent with the conclusion that Y P XXQ-mediated Stat3 recruitment and activation are necessary for gp130 dierentiation signaling in M1 cells.
Although gp130-induced Stat3 activation correlates with growth arrest and terminal dierentiation of M1 myeloid leukemia cells, this pathway produces opposing actions in other cell types. For example, Stat3 has been implicated in the maintenance of totipotency and suppression of dierentiation in embryonic stem (ES) cells. Ernst et al. (1999) provide evidence linking Stat3 activation and suppression of ES cell dierentiation using a chimeric receptor strategy similar to that described above for the M1 macrophage dierentiation model. For these studies, chimeras were created by fusing the extracellular ligand-binding domain of the G-CSF receptor to the cytoplasmic region of gp130 or to the homologous LIF receptor a-chain (LIF-Ra). Undierentiated ES cells do not express the G-CSF receptor, allowing for analysis of signaling without interference from endogenous gp130 or LIF-Ra. Both chimeric receptors were able to suppress dierentiation of ES cells in response to G-CSF, as did a G-CSF receptor chain, indicating that the cytoplasmic domains of all three receptors produce signals sucient for the maintenance of totipotency. Using C-terminal truncation mutants of the gp130 chimeras, G-CSF-dependent suppression of dierentiation was shown to require at least two of the four Y P XXQ motifs in the gp130 cytoplasmic region. A deletion mutant retaining only a single Y P XXQ motif around Tyr 126 was signi®cantly impaired, and mutation of this Tyr to Phe abolished signaling entirely from the truncated receptor. Cterminal deletions within the LIF-Ra chimera produced similar results. In both cases, C-terminal truncations that interfered with suppression of dierentiation correlated with a loss of Stat3 activation. Interestingly, chimeric receptor deletion constructs unable to activate Stat3 and devoid of dierentiation-suppressing activity retained the ability to induce proliferative responses in an IL-6-dependent cell line. These data indicate that signals for suppression of dierentiation in ES cells involve Stat3 and are distinct from those controlling proliferation. Further evidence for this hypothesis comes from studies with dominant-negative Stat3 mutants.
G-CSF receptor
G-CSF regulates the dierentiation of myeloid progenitor cells to neutrophilic granulocytes. In addition, it enhances the survival and functional activities of mature neutrophils (Avalos, 1996) . The receptor for G-CSF consists of a single polypeptide chain with extracellular features typical of cytokine receptors, including an Ig-like domain, conserved cysteines and a WSXWS motif, as well as ®bronectin type III domains. The membrane-proximal region of the cytoplasmic domain contains the box 1/box 2 motif often associated with Jak kinase activation, while the more distal portion of the cytoplasmic domain contains several tyrosine phosphorylation sites.
The murine M1 myeloid leukemia cell line described in the previous section has also been used to dissect G-CSF receptor-mediated Stat activation and dierentiation signaling. Following transfection with the G-CSF receptor, M1 leukemia cells dierentiate into macrophages following G-CSF treatment in a manner analogous to treatment with LIF. Nicholson et al. (1996) replaced each of the four tyrosine residues in the G-CSF receptor cytoplasmic domain individually or in combination, and assayed dierentiation as well as Stat3 tyrosine phosphorylation. They found that substitution of Tyr 744 signi®cantly impaired G-CSFinduced dierentiation. However, Stat3 was still phosphorylated on tyrosine following activation of the dierentiation-defective receptor. In fact, a receptor mutant lacking all four tyrosine residues retained the ability to induce Stat3 tyrosine phosphorylation and DNA-binding activity. This ®nding suggests that direct interaction with the G-CSF receptor may not be absolutely required for Stat3 activation. One alternative route of Stat3 activation may involve interaction with receptor-associated tyrosine kinases. However, other work has shown that tyrosine phosphopeptides based on G-CSF receptor sequences surrounding Tyr 744 and Tyr 704 interact with the Stat3 SH2 domain (Chakraborty et al., 1999) . Thus, direct recruitment by the receptor may contribute to Stat3 activation by G-CSF under some circumstances.
The ®nding that dierentiation-defective G-CSF receptors retain the ability to activate Stat3 contrasts with similar studies of gp130 dierentiation signaling described above . One possible explanation for this dierence is that the mutant G-CSF receptors may be sucient to induce Stat3 tyrosine phosphorylation and DNA binding but not transcriptional activation. Maximal transcriptional activity of Stat3 depends not only on tyrosine phosphorylation, but on serine phosphorylation as well (Wen et al., 1995) . Turkson et al. (1999) have recently shown that the p38 and Jnk serine/threonine kinase pathways are critical for full Stat activation in v-Src transformed cells. However, inhibition of serine phosphorylation did not aect Stat3 DNA binding activity, consistent with earlier reports (Wen and Darnell, 1997) . The G-CSF receptor mutants described by Nicholson et al. (1996) may be unable to activate these or other serine/threonine kinases required for transcriptional activation of Stat3. Indeed, more recent studies with dominant-negative Stat3 mutants suggest a requirement for Stat3 activation in G-CSF induced dierentiation (Shimozaki et al., 1997; see below) .
Epo receptor
Epo regulates the survival, proliferation and dierentiation of erythroid progenitors (Lacombe and Mayeux, 1998) . The receptor for Epo consists of a single polypeptide chain with a high degree of homology to the receptors for Tpo and G-CSF. Receptor activation and signal transduction are initiated as a result of Epoinduced receptor dimerization and activation of associated non-receptor protein-tyrosine kinases, especially those of the Jak family. In fact, the Epo receptor was among the ®rst examples of cytokine receptors shown to be coupled to the activation of Jak kinases (Miura et al., 1994; Witthuhn et al., 1993) .
A number of studies have linked Epo to the activation of Stat5, although the requirement for Stat5 in erythroid dierentiation is somewhat controversial. Iwatsuki et al. (1997) demonstrated that erythroid dierentiation driven by chimeric EGF-Epo receptors correlated with Stat5 activation in the ELM-I-1 erythroleukemia cell line. This cell line reproduces several aspects of normal erythroid dierentiation following treatment with Epo, including hemoglobin synthesis and nuclear extrusion (Shiozaki et al., 1990) . Using a large panel of EGF-Epo receptor chimeras, a strong correlation was observed between dierentiation-inducing activity and Stat5 activation. In particular, Tyr 343 and Tyr 401 were found to be important for dierentiation and Stat5 activation as well as induction of cis, a cytokine-inducible immediate early gene that is regulated by Stat5 (Yoshimura et al., 1995; Quelle et al., 1996) . This gene encodes a 37 kDa protein with an SH2 domain that binds to tyrosinephosphorylated cytokine receptors, including the Epo receptor. Over-expression of the Cis protein was found to reduce the growth rate of IL-3-dependent cell lines, suggesting a function in the negative regulation of cell proliferation (Yoshimura et al., 1995) . Whether Stat5-induced cis expression directly contributes to the Epoinduced dierentiation response observed in ELM-I-1 cells is not known.
In related studies, Gregory et al. (1998) observed a strong correlation between Stat5 activation and Epoinduced hemoglobinization of the murine erythroleukemia cell line, SKT6. Using chimeric EGF-Epo receptor chimeras, these workers demonstrated that a large C-terminal truncation did not abolish the dierentiation-inducing activity of the receptor, despite the loss of seven tyrosine residues. In fact, dierentiation responses to the truncated chimera were markedly enhanced. This observation probably results from the loss of SH2 recruitment sites for the hematopoietic cell phosphatase, an important negative regulator of Epo signaling (Neel and Tonks, 1997; Tonks and Neel, 1996) . Epo signaling through the truncated receptor correlated with the activation of Stat5. Mutation of the Stat5 binding site in the truncated chimera (Tyr 343) inhibited Epo-induced hemoglobinization, supporting a requirement for Stat5 in some Epo-dependent dierentiation responses.
In contrast to these ®ndings, ChreÂ tien et al. (1996) found that Stat5 activation interfered with Epoinduced dierentiation of the human erythroleukemia cell line, TF-1. TF-1 cells express high levels of a truncated Epo receptor as a consequence of a translocation (Winkelmann et al., 1995) . This truncation results in the deletion of 96 C-terminal amino acids, including seven tyrosine residues. An additional mutation replaces Leu 347 with Pro, which is in the +3 position relative to Tyr 344 (equivalent of Tyr 343 in the murine receptor). This change could aect the anity of this putative binding site for the Stat5 SH2 domain. Treatment of parental TF-1 cells with Epo resulted in erythroid dierentiation. However, Stat5 was not activated in response to Epo treatment, presumably because of the receptor mutations. Introduction of the wild-type Epo receptor with a recombinant retrovirus restored Stat5 activation and caused the cells to proliferate following Epo treatment, while the dierentiation response was greatly diminished. Thus, the dominant response to Epo in TF-1 cells is survival and proliferation as opposed to dierentiation.
These and other studies implicate murine Epo receptor tyrosine residues Tyr 343 and Tyr 401 in Stat5 activation Damen et al., 1995; Quelle et al., 1996; Klingmuller et al., 1996) . Although the myeloid leukemia cell lines used in these studies exhibit great variability in their responses to Epo-mediated Stat5 activation, cell lines that respond with erythroid dierentiation (e.g., ELM-I-1; SKT6) exhibit characteristics that more closely resemble committed erythroid progenitors.
Dominant-negative Stat mutants
Dominant-negative Stat mutants have been used to address the requirement for Stat activation in a number of studies related to cytokine-induced dierentiation and survival. Several types of mutations can produce an eective dominant-negative Stat protein, and these are illustrated in Figure 1 . Phenylalanine substitution of the conserved tyrosine phosphorylation site near the C-terminus of the molecule results in a mutant that competes with endogenous Stats for binding to SH2 recruitment sites on activated receptors. Mutants lacking glutamic acid residues essential for DNA binding are also eective. In this case, tyrosine phosphorylation still occurs, leading to the formation of mutant-wild-type heterodimers that are unable to bind to DNA. Another strategy involves truncation of C-terminal residues that are involved in transcriptional transactivation. These mutants are tyrosine-phosphorylated and bind to DNA, but are unable to in¯uence transcription and compete for promoter binding with endogenous Stats. Stat3b is a naturally occurring splice variant of Stat3 that lacks these C-terminal residues (Caldenhoven et al., 1996) .
Dominant-negative mutants implicate Stat3 in myeloid differentiation
Studies with dominant-negative mutants suggest a necessary role for Stat3 in myeloid dierentiation. Nakajima et al. (1996) utilized Stat3 mutants lacking the tyrosine phosphorylation site (Tyr 705?Phe; Stat3F mutant) or with Ala substitutions for Glu residues essential for DNA binding (Stat3D mutant). Both mutants blocked IL-6-induced activation of endogenous Stat3 following expression in M1 myeloid leukemia cells as assessed by electrophoretic mobility shift assay. As expected, the Stat3F mutant suppressed tyrosine phosphorylation of endogenous Stat3, thus preventing nuclear translocation and DNA binding. On the other hand, the Stat3D mutant was tyrosine phosphorylated and translocated into the nucleus, where it suppressed endogenous Stat3 function at the level of DNA binding. Both Stat3 mutants blocked morphological dierentiation of M1 myeloid leukemia cells in response to IL-6. These results strongly suggest that Stat3 activation is required for IL-6-induced dierentiation in the M1 macrophage model. Interest- Chen et al., 1998; Becker et al., 1998) , the overall organization of Stats consists of an N-terminal domain (N) involved in cooperative binding to DNA, a four-helix bundle (4HB), a b-barrel (bBBL) which forms loops involved in DNA binding, the SH2 domain (SH2) and conserved tyrosine phosphorylation site (Y P ) which are essential for dimerization, and a C-terminal region involved in transactivation of transcription (AD). Three types of dominant-negative mutants are illustrated. Mutation of the conserved tyrosine residue to phenylalanine produces dimerization-defective mutants that compete with endogenous Stats for SH2 recruitment sites at cytokine receptors. Mutation of conserved glutamic acid residues (or other sites) within the b-barrel domain interfere with DNA binding and block endogenous Stat signaling by forming deadend dimers. C-terminal truncation removes sequences essential for transcriptional activation. Such mutants presumably work by blocking access of the wild-type Stat dimer to promoter elements ingly, M1 cells expressing the Stat3 dominant-negative mutants proliferated more rapidly as a result of shortening of the G1 phase of the cell cycle. This ®nding indicates that IL-6/gp130 can generate mitogenic and dierentiation signals in M1 cells and that the signal for dierentiation is dominant over the signal for proliferation. Minami et al. (1996) observed very similar results with M1 cells over-expressing the identical Stat3F mutant as well as a truncation mutant lacking the Cterminal transcriptional activation domain and the major serine phosphorylation site. Both Stat3 mutants completely blocked IL-6 and LIF-induced growth arrest and expression of dierentiation markers. A Stat3 mutant with a larger C-terminal deletion encompassing the tyrosine phosphorylation site and SH2 domain was inactive as a dominant-negative mutant, consistent with the inhibitory mechanisms described in Figure 1 . Dominant-negative mutants have also demonstrated a requirement for Stat3 activation in the dierentiation response to G-CSF. Shimozakai et al. (1997) used mouse myeloid LGM-1 cells stably transfected with the G-CSF receptor as a model system. Treatment of these cells with G-CSF induces growth arrest and dierentiation to cells with the morphology of neutrophilic granulocytes. Expression of Stat3 mutants lacking the tyrosine phosphorylation site or defective in DNA binding completely suppressed morphological dierentiation in response to G-CSF. Interestingly, cells expressing the dominant-negative mutants continued to proliferate in the presence of G-CSF, indicating that G-CSF generates a signal for proliferation and survival in these cells that does not require activation of Stat3. These results are similar to those described above for gp130-mediated dierentiation of M1 myeloid leukemia cells.
Work by Shimozaki et al. (1997) , described above, suggests that G-CSF-induced Stat3 activation may drive neutrophilic dierentiation directly. However, recent work with bone marrow progenitors suggests a more permissive role for Stat3. Transduction of murine bone marrow cells with retroviruses carrying the Stat3F and Stat3D dominant-negative mutants described above suppressed the number and size of the dierentiated colonies formed in soft-agar assays in response to G-CSF. However, morphologically dierentiated granulocytes were still present, suggesting that Stat3 transmits G-CSF signals for growth and survival but not for dierentiation per se (Link and Liu, 1999) .
Although dominant-negative mutants have established a necessary role for Stat3 in myeloid dierentiation and survival, the same mutants suppress dierentiation in ES cells. Using a Stat3 mutant lacking the conserved tyrosine phosphorylation site, Niwa et al. (1998) demonstrated that Stat3 activation is required for LIF/gp130-induced maintenance of ES cell totipotency. Expression of this Stat3 mutant induced formation of dierentiated colonies from ES cells in the presence of LIF, and this eect was reversed following co-expression of wild-type Stat3. The eect was speci®c for Stat3, as co-expression of Stat1 or Stat4 was unable to restore self-renewal in response to LIF. The opposing action of Stat3 in ES cells relative to other cell types is likely to re¯ect dierences in target genes that are induced in dierent cellular contexts. It will be of interest to determine if active Stat3 alone is sucient for suppression of ES cell dierentiation.
Dominant-negative Stat5 blocks Epo-induced differentiation in some cell lines
A dominant-negative form of Stat5 has been shown to suppress Epo-induced dierentiation in the ELM-I-1 erythroleukemia cell line described above (Iwatsuki et al., 1997) . These studies utilized a Stat5 mutant lacking the C-terminal transactivation domain, which produced a marked suppression of Epo-induced hemoglobin synthesis. In contrast, over-expression of wild-type Stat5 did not produce a signi®cant eect. More recently, Gregory et al. (1998) showed that dominantnegative forms of Stat5 lacking either the DNA binding or the transactivation function markedly suppressed Epo-induced hemoglobinization in murine SKT6 cells. A Stat3 dominant-negative mutant did not block this Epo-dependent response, arguing for a Stat5-selective eect (Gregory et al., 1998) . Although these data demonstrate a requirement for Stat5 in the dierentiation of Epo-responsive cell lines, more recent work with Stat5 knock-out mice suggests that the primary function for Stat5 in Epo signaling may involve suppression of apoptosis in erythroid progenitors (see below).
Stat signaling in myeloid cell survival

Stat5 activation is required for survival of erythroid progenitors
Recent studies of Stat5 knock-out mice have established an important role for Stat5 activation during fetal development of erythroid progenitors (Socolovsky et al., 1999; Teglund et al., 1998) . Socolovsky et al. (1999) observed that embryos from mice with homozygous disruptions of both Stat5 genes (Stat5a
) are anemic as a result of reduced responsiveness to the antiapoptotic eect of Epo. To determine whether the fetal anemia observed in the knock-out animals was a direct result of the loss of Stat5 function in erythroid progenitors, dominant-negative forms of Stat5 were introduced into wild-type fetal liver cells and monitored for Epo-dependent growth and survival. Cells expressing dominant-negative Stat5 showed an enhanced rate of apoptosis as well as reduced net growth in response to Epo, consistent with the results of the Stat5 knock-out. These results provide strong evidence that activation of Stat5 is essential for Epo-induced growth and survival of primary erythroid progenitors in fetal liver.
Previous studies have suggested that Epo-induced survival signaling in both erythroid progenitors and Epo-dependent cell lines correlates with induction of the anti-apoptotic gene Bcl-X L (Silva et al., 1996; Gregoli and Bondurant, 1997) . Socolvosky et al. (1999) extended these ®ndings to show that Bcl-X L induction is dependent upon Stat5 activation. Stat5 consensus binding sites were identi®ed in the Bcl-X L promoter region, and oligonucleotides based on these sequences were shown to bind to Stat5 in an electrophoretic mobility shift assay. Epo was observed to enhance transcription from reporter plasmids containing the Stat5 consensus binding region. Mutation of these sites obliterated the enhancement of transcription, indicating that Stat5 binding sites are necessary and sucient for Epo-induced transcription from the Bcl-X L promoter. Dominant-negative Stat5 was also shown to suppress Epo-induced transcription of endogenous Bcl-X L and Cis (Yoshimura et al., 1995) . Conversely, stable expression of a constitutively active form of Stat5 (Onishi et al., 1998) protected the Epo-dependent cell line HCD-57 from apoptosis following Epo withdrawal. This protective eect of Stat5a correlated with induction of Bcl-X L . Recent work by Silva et al. (1999) produced similar results in the HCD-57 cell line as well as Ba/F3 cells ectopically expressing the Epo receptor. Taken together, these results strongly implicate Bcl-X L as an important target gene for Stat5 in Epo-induced cell survival.
Although the work summarized above strongly implicates Stat5 in fetal erythropoiesis, adult mice with the identical targeted deletions of Stat5a and 5b exhibit normal numbers of circulating red cells as well as other myeloid cell types (Teglund et al., 1998) . However, bone marrow from adult Stat5a
7/7 mice contains twice the normal number of early red-cell progenitors (Teglund et al., 1998) , which may re¯ect a compensatory mechanism for the reduced survival of these cells (Socolovsky et al., 1999) . In addition, increased levels of other Stats may compensate in terms of the Bcl-X L induction required for survival. Recent work has shown that both Stat1 and Stat3 binding sites exist in the Bcl-X L promoter (Catlett-Falcone et al., 1999; Fujio et al., 1997) .
A requirement for Stat3 in gp130-mediated survival signaling
In addition to promoting dierentiation, Stat3 has been implicated in survival signaling from the IL-6/ gp130 cytokine receptor system. Using a series of chimeric receptors which fused the ligand-binding domain of the G-CSF receptor to the cytoplasmic portion of gp130, Fukada et al. (1996) demonstrated that activation of Stat3 correlated with G-CSF-induced survival responses in transfected BAF-B03 cells, an IL-6-responsive murine pro-B cell line. In particular, a truncated chimera retaining only a single Stat3 recruitment site retained the capacity for survival signaling. Mutation of the tyrosine in the Y P XXQ motif de®ned by this site uncoupled the receptor from Stat3 activation and blocked the G-CSF survival signal. Using dominant-negative mutants, this study also demonstrated a requirement for Stat3 activation in the anti-apoptotic response. Induction of Bcl-2 was shown to correlate with Stat3 activation and survival in this cell line. Whether or not this anti-apoptotic gene is a direct target for Stat3 was not examined.
In related studies, Catlett-Falcone et al. (1999) showed that autocrine activation of the IL-6/gp130 pathway renders human multiple myeloma cells resistant to Fas-induced apoptosis. This response correlated with constitutive activation of Stat3 and was blocked by a Jak kinase-selective inhibitor (AG490), demonstrating a necessary role for Stat3 in the protective mechanism. A dominant-negative form of Stat3 was shown to block both the survival response as well as transcriptional activation of Bcl-X L , de®ning a survival signaling pathway from the IL-6 receptor through Stat3 to the expression of this anti-apoptotic gene. Constitutive Stat3 activation was observed in bone marrow samples from many multiple myeloma patients in this study, suggesting that Stat3 may contribute generally to the pathogenesis of multiple myeloma through an anti-apoptotic mechanism (reviewed by Jove and Bowman, this volume).
Stat activation by Src kinases in myeloid cell survival
Members of the Src kinase family may couple cytokine receptors to Stat activation and survival signaling (Corey and Anderson, 1999) . For example, IL-3-dependent survival has been shown to correlate with the activation of both c-Src and Stat3 in the murine myeloblast cell line, 32Dcl3. Activation of Stat3 by IL-3 in this system is blocked by a dominant-negative form of c-Src but not of Jak2, suggesting a pathway from the receptor to Stat3 through c-Src (Chaturvedi et al., 1998) . Transformation of myeloid leukemia cell lines to cytokine-independence by constitutively active Src kinases also correlates with Stat activation. Induction of IL-3 independence in 32Dcl3 cells by vSrc correlates with constitutive activation of Stats 1, 3 and 5 (Chaturvedi et al., 1997) . Interestingly, the tyrosine phosphorylation state of Jak kinases was unaected in the v-Src transformed cells, suggesting that Stats are direct targets for v-Src in these cells. These and other studies have also shown that Stat3 stably associates with both v-Src and c-Src, supporting a direct relationship between Src kinases and Stat activation (Cao et al., 1996) .
Work from our laboratory also supports a direct connection between Src kinases, Stat activation and survival signaling. These studies involved the Nef protein of HIV-1, a small myristylated protein that plays a critical role in AIDS progression (Stevenson, 1996; Saksela, 1997) . Nef binds with high anity to the SH3 domain of the myeloid-speci®c Src family member Hck, leading to its activation both in vitro and in vivo (Briggs et al., 1997; Briggs and Smithgall, 1999; Moare® et al., 1997) . Recently, we observed that Nef can transform the GM-CSF-dependent myeloid leukemia cell line TF-1 to cytokine independence by blocking apoptosis that would otherwise result from cytokine withdrawal (Briggs S, Scholtz B, Jacque J-M, Swingler S, Stevenson M and Smithgall TE, manuscript submitted). Nef induced constitutive activation of Stat3 in the cytokine-independent cells, an eect which correlated with activation of endogenous Hck. The Nef survival signal was blocked by dominantnegative Stat3 mutants, indicating a requirement for Stat3 activation. Co-expression with Hck strongly induced Stat3 activation in a de®ned expression system, consistent with the hypothesis that Nef-induced Hck activation may directly trigger Stat3 activation in vivo. Interestingly, work by Ernst et al. (1999) shows that the regions of gp130 required for Stat3 activation are also required for the activation of Hck in ES cells. Thus, Hck may normally contribute to Stat3 activation in response to some gp130-linked cytokines.
Studies summarized above suggest that tyrosine kinases other than Jaks may contribute to Stat activation in some systems. In addition to Src, the non-receptor tyrosine kinase encoded by the c-fes proto-oncogene may also contribute to Stat3 activation. Fes exhibits strong expression in myeloid hematopoietic cells and is activated in response to GM-CSF, IL-6 and other cytokines . Fes expression is sucient to induce dierentiation of K-562 myeloid leukemia cells (Cheng et al., 1999; Yu et al., 1989) and may be required for dierentiation and survival signaling in other myeloid cell lines (Manfredini et al., 1993 (Manfredini et al., , 1997 . We have observed that Fes strongly induces Stat3 activation following co-expression of the proteins in either 293T cells or using a baculovirus/Sf-9 cell system (Nelson et al., 1998) . In addition, expression of constitutively active mutants of Fes is sucient to induce survival and dierentiation responses in the GM-CSF-dependent cell line, TF-1 (Cheng H and Smithgall TE, unpublished data) . Interestingly, macrophages from mice with a targeted inactivating mutation in the c-fes locus demonstrated a complete loss of Stat3 activation in response to GM-CSF (Sensis et al., 1999) . This result suggests a non-redundant role for Fes in the activation of Stat3 in response to some cytokines in vivo.
Discussion
Studies summarized above strongly implicate Stat activation in the survival and dierentiation of myeloid hematopoietic cells. While myeloid leukemia cell lines provide a useful model system to address mechanistic details of receptor-kinase-Stat coupling, studies with bone marrow cultures and knock-out mice are essential for the analysis of Stat signaling in myeloid dierentiation under physiological conditions. One particularly intriguing yet unresolved issue regards the opposing actions of Stats in dierent cellular backgrounds. The dierentiation responses of ES cells vs myeloid leukemia cell lines to Stat3 activation provides a striking illustration of this paradox. Combining the power of gene-chip microarray technology (Brown and Botstein, 1999) with constitutively active Stat mutants (Bromberg et al., 1999; Onishi et al., 1998) will allow for a global analysis of gene expression induced by Stats in these and other cell types.
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